Laboratory and clinical details at the time of LT in 91 patients with MMM
Patient characteristics . | Data . |
|---|---|
| Method of LT diagnosis, no. (%) | |
| Bone marrow examination | 78 (86) |
| Peripheral blood examination | 13 (14) |
| Median peripheral blood counts | |
| Hemoglobin, g/L (range) | 92 (45-140) |
| Erythrocyte transfusion dependent, no. (%) | 59 (65) |
| Leukocyte count, × 109/L (range) | 4.9 (0.1-113.3) |
| Greater than 20 × 109/L, no. (%) | 43 (47) |
| Circulating myeloblasts (range) | 25 (0-92) |
| Platelet count, × 109/L (range) | 68 (4-797) |
| Less than 100 × 109/L, no. (%) | 60 (66) |
| Less than 50 × 109/L, no. (%) | 33 (36) |
| Median spleen and liver sizes, cm below the respective costal margins (range) | |
| Spleen | 6 (0-27) |
| Liver | 2 (0-20) |
| Bone marrow findings, % (range) | |
| Median marrow cellularity | 80 (5-95) |
| Median marrow myeloblast percentage | 43 (20-95) |
| Reticulin fibrosis of at least grade 2 | 37.5 |
| Osteosclerosis present | 30.3 |
| FAB classification of AML, no. patients (%) | |
| Total | 67 (100.0) |
| M0 | 15 (22.4) |
| M1 | 9 (13.4) |
| M2 | 12 (17.9) |
| M3 | 0 (0.0) |
| M4 | 8 (11.9) |
| M5 | 3 (4.5) |
| M6 | 3 (4.5) |
| M7 | 17 (25.4) |
| No. bone marrow karyotypic abnormalities, no. patients (%) | |
| Total | 53 (100.0) |
| Normal karyotype | 5 (9.4) |
| 1 | 16 (30.1) |
| 2 | 3 (5.6) |
| 3 or more | 29 (54.9) |
Patient characteristics . | Data . |
|---|---|
| Method of LT diagnosis, no. (%) | |
| Bone marrow examination | 78 (86) |
| Peripheral blood examination | 13 (14) |
| Median peripheral blood counts | |
| Hemoglobin, g/L (range) | 92 (45-140) |
| Erythrocyte transfusion dependent, no. (%) | 59 (65) |
| Leukocyte count, × 109/L (range) | 4.9 (0.1-113.3) |
| Greater than 20 × 109/L, no. (%) | 43 (47) |
| Circulating myeloblasts (range) | 25 (0-92) |
| Platelet count, × 109/L (range) | 68 (4-797) |
| Less than 100 × 109/L, no. (%) | 60 (66) |
| Less than 50 × 109/L, no. (%) | 33 (36) |
| Median spleen and liver sizes, cm below the respective costal margins (range) | |
| Spleen | 6 (0-27) |
| Liver | 2 (0-20) |
| Bone marrow findings, % (range) | |
| Median marrow cellularity | 80 (5-95) |
| Median marrow myeloblast percentage | 43 (20-95) |
| Reticulin fibrosis of at least grade 2 | 37.5 |
| Osteosclerosis present | 30.3 |
| FAB classification of AML, no. patients (%) | |
| Total | 67 (100.0) |
| M0 | 15 (22.4) |
| M1 | 9 (13.4) |
| M2 | 12 (17.9) |
| M3 | 0 (0.0) |
| M4 | 8 (11.9) |
| M5 | 3 (4.5) |
| M6 | 3 (4.5) |
| M7 | 17 (25.4) |
| No. bone marrow karyotypic abnormalities, no. patients (%) | |
| Total | 53 (100.0) |
| Normal karyotype | 5 (9.4) |
| 1 | 16 (30.1) |
| 2 | 3 (5.6) |
| 3 or more | 29 (54.9) |
FAB indicates French-American-British cooperative group; and AML, acute myeloid leukemia.